{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T07:23:01Z","timestamp":1784618581143,"version":"3.55.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Endogenous Cushing\u2019s syndrome (CS) is a rare endocrine condition frequently caused by a tumor resulting in elevated cortisol levels. Cushing\u2019s disease (CD) caused by an adrenocorticotropic hormone\u2013secreting pituitary adenoma is the most common form of endogenous CS. Medical therapy for CD is mostly used as second-line treatment after failed surgery or recurrence and comprises several pituitary-directed drugs, adrenal steroidogenesis inhibitors, and a glucocorticoid receptor blocker, some of which are US Food and Drug Administration (FDA)\u2013approved for this condition. The recent Pituitary Society consensus guidelines for diagnosis and management of CD described osilodrostat, an oral inhibitor of 11\u03b2-hydroxylase, as an effective, FDA-approved medical therapy for CD. Because clinical experience outside clinical trials is limited, we provide here a review of published data about osilodrostat and offer example case studies demonstrating practical considerations on the use of this medication. Recommendations regarding osilodrostat are provided for the following situations: specific assessments needed before treatment initiation; monitoring for adrenal insufficiency, hypokalemia, and changes in QTc; the potential value of a slow up-titration in patients with mild disease; managing temporary treatment cessation for patients with CD who have acquired coronavirus disease 2019; monitoring for increased testosterone levels in women; exercising caution with concomitant medication use; considering whether a higher dose at nighttime might be beneficial; and managing cortisol excess in ectopic and adrenal CS. This review highlights key clinical situations that physicians may encounter when using osilodrostat and provides practical recommendations for optimal patient care when treating CS, with a focus on CD.<\/jats:p>","DOI":"10.1007\/s11102-022-01268-2","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T20:02:30Z","timestamp":1661371350000},"page":"795-809","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Treatment of Cushing\u2019s syndrome with osilodrostat: practical applications of recent studies with case examples"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9284-6289","authenticated-orcid":false,"given":"Maria","family":"Fleseriu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4359-4622","authenticated-orcid":false,"given":"Beverly M. K.","family":"Biller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"issue":"12","key":"1268_CR1","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR et al (2021) Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol 9(12):847\u2013875. https:\/\/doi.org\/10.1016\/S2213-8587(21)00235-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1268_CR2","doi-asserted-by":"publisher","first-page":"101490","DOI":"10.1016\/j.beem.2021.101490","volume":"35","author":"EV Varlamov","year":"2021","unstructured":"Varlamov EV, Han AJ, Fleseriu M (2021) Updates in adrenal steroidogenesis inhibitors for Cushing\u2019s syndrome\u2014a practical guide. Best Pract Res Clin Endocrinol Metab 35(1):101490. https:\/\/doi.org\/10.1016\/j.beem.2021.101490","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"10","key":"1268_CR3","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1056\/NEJMra1810772","volume":"382","author":"S Melmed","year":"2020","unstructured":"Melmed S (2020) Pituitary-tumor endocrinopathies. N Engl J Med 382(10):937\u2013950. https:\/\/doi.org\/10.1056\/NEJMra1810772","journal-title":"N Engl J Med"},{"issue":"7","key":"1268_CR4","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1210\/clinem\/dgab122","volume":"106","author":"F Castinetti","year":"2021","unstructured":"Castinetti F, Nieman LK, Reincke M, Newell-Price J (2021) Approach to the patient treated with steroidogenesis inhibitors. J Clin Endocrinol Metab 106(7):2114\u20132123. https:\/\/doi.org\/10.1210\/clinem\/dgab122","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1268_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1210\/clinem\/dgaa778","volume":"106","author":"NA Tritos","year":"2021","unstructured":"Tritos NA (2021) Adrenally directed medical therapies for Cushing syndrome. J Clin Endocrinol Metab 106(1):16\u201325. https:\/\/doi.org\/10.1210\/clinem\/dgaa778","journal-title":"J Clin Endocrinol Metab"},{"key":"1268_CR6","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac178","author":"M Gadelha","year":"2022","unstructured":"Gadelha M, Bex M, Feelders RA, Heaney AP, Auchus RJ, Gilis-Januszewska A et al (2022) Randomized trial of osilodrostat for the treatment of Cushing\u2019s disease. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgac178","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1268_CR7","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1210\/jc.2013-2117","volume":"99","author":"X Bertagna","year":"2014","unstructured":"Bertagna X, Pivonello R, Fleseriu M, Zhang Y, Robinson P, Taylor A et al (2014) LCI699, a potent 11beta-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing\u2019s disease: results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab 99(4):1375\u20131383. https:\/\/doi.org\/10.1210\/jc.2013-2117","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1268_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s11102-015-0692-z","volume":"19","author":"M Fleseriu","year":"2016","unstructured":"Fleseriu M, Pivonello R, Young J, Hamrahian AH, Molitch ME, Shimizu C et al (2016) Osilodrostat, a potent oral 11beta-hydroxylase inhibitor: 22-week, prospective, phase II study in Cushing\u2019s disease. Pituitary 19(2):138\u2013148. https:\/\/doi.org\/10.1007\/s11102-015-0692-z","journal-title":"Pituitary"},{"issue":"9","key":"1268_CR9","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","volume":"8","author":"R Pivonello","year":"2020","unstructured":"Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A et al (2020) Efficacy and safety of osilodrostat in patients with Cushing\u2019s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol 8(9):748\u2013761. https:\/\/doi.org\/10.1016\/S2213-8587(20)30240-0","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1268_CR10","unstructured":"Recordati (2020) Isturisa prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212801s000lbl.pdf"},{"issue":"2","key":"1268_CR11","doi-asserted-by":"publisher","first-page":"313","DOI":"10.4158\/ep12149.Ra","volume":"19","author":"M Fleseriu","year":"2013","unstructured":"Fleseriu M, Molitch ME, Gross C, Schteingart DE, Vaughan TB 3rd, Biller BM (2013) A new therapeutic approach in the medical treatment of Cushing\u2019s syndrome: glucocorticoid receptor blockade with mifepristone. Endocr Pract 19(2):313\u2013326. https:\/\/doi.org\/10.4158\/ep12149.Ra","journal-title":"Endocr Pract"},{"issue":"4","key":"1268_CR12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1080\/17446651.2021.1945440","volume":"16","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Auchus RJ, Pivonello R, Salvatori R, Zacharieva S, Biller BMK (2021) Levoketoconazole: a novel treatment for endogenous Cushing\u2019s syndrome. Expert Rev Endocrinol Metab 16(4):159\u2013174. https:\/\/doi.org\/10.1080\/17446651.2021.1945440","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"2","key":"1268_CR13","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s11102-013-0483-3","volume":"17","author":"A Colao","year":"2014","unstructured":"Colao A, De Block C, Gaztambide MS, Kumar S, Seufert J, Casanueva FF (2014) Managing hyperglycemia in patients with Cushing\u2019s disease treated with pasireotide: medical expert recommendations. Pituitary 17(2):180\u2013186. https:\/\/doi.org\/10.1007\/s11102-013-0483-3","journal-title":"Pituitary"},{"issue":"3","key":"1268_CR14","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11102-014-0582-9","volume":"18","author":"L Trementino","year":"2015","unstructured":"Trementino L, Cardinaletti M, Concettoni C, Marcelli G, Boscaro M, Arnaldi G (2015) Up-to 5-year efficacy of pasireotide in a patient with Cushing\u2019s disease and pre-existing diabetes: literature review and clinical practice considerations. Pituitary 18(3):359\u2013365. https:\/\/doi.org\/10.1007\/s11102-014-0582-9","journal-title":"Pituitary"},{"issue":"10","key":"1268_CR15","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1210\/jc.2015-2107","volume":"100","author":"FG Amlashi","year":"2015","unstructured":"Amlashi FG, Swearingen B, Faje AT, Nachtigall LB, Miller KK, Klibanski A et al (2015) Accuracy of late-night salivary cortisol in evaluating postoperative remission and recurrence in Cushing\u2019s disease. J Clin Endocrinol Metab 100(10):3770\u20133777. https:\/\/doi.org\/10.1210\/jc.2015-2107","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1268_CR16","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.1210\/jc.2015-2616","volume":"100","author":"E Daniel","year":"2015","unstructured":"Daniel E, Aylwin S, Mustafa O, Ball S, Munir A, Boelaert K et al (2015) Effectiveness of metyrapone in treating Cushing\u2019s syndrome: a retrospective multicenter study in 195 patients. J Clin Endocrinol Metab 100(11):4146\u20134154. https:\/\/doi.org\/10.1210\/jc.2015-2616","journal-title":"J Clin Endocrinol Metab"},{"key":"1268_CR17","unstructured":"Xeris Pharmaceuticals (2021) Recorlev prescribing information. https:\/\/www.recorlev.com\/full-prescribing-information.pdf"},{"issue":"1","key":"1268_CR18","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1210\/jc.2006-1328","volume":"92","author":"G Assi\u00e9","year":"2007","unstructured":"Assi\u00e9\u00a0G, Bahurel H, Coste J, Silvera S, Kujas M, Dugue MA et al (2007) Corticotroph tumor progression after adrenalectomy in Cushing\u2019s disease: a reappraisal of Nelson\u2019s syndrome. J Clin Endocrinol Metab 92(1):172\u2013179. https:\/\/doi.org\/10.1210\/jc.2006-1328","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1268_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJM195807242590403","volume":"259","author":"DH Nelson","year":"1958","unstructured":"Nelson DH, Meakin JW, Dealy JB Jr, Matson DD, Emerson K Jr, Thorn GW (1958) ACTH-producing tumor of the pituitary gland. N Engl J Med 259(4):161\u2013164. https:\/\/doi.org\/10.1056\/NEJM195807242590403","journal-title":"N Engl J Med"},{"issue":"10","key":"1268_CR20","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1210\/jc.2014-1843","volume":"99","author":"M Fleseriu","year":"2014","unstructured":"Fleseriu M, Findling JW, Koch CA, Schlaffer SM, Buchfelder M, Gross C (2014) Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing\u2019s disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone. J Clin Endocrinol Metab 99(10):3718\u20133727. https:\/\/doi.org\/10.1210\/jc.2014-1843","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1268_CR21","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1210\/jc.2019-00217","volume":"104","author":"SG Creemers","year":"2019","unstructured":"Creemers SG, Feelders RA, de Jong FH, Franssen GJH, de Rijke YB, van Koetsveld PM, Hofland LJ (2019) Osilodrostat is a potential novel steroidogenesis inhibitor for the treatment of Cushing syndrome: an in vitro study. J Clin Endocrinol Metab 104(8):3437\u20133449. https:\/\/doi.org\/10.1210\/jc.2019-00217","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1268_CR22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11102-020-01097-1","volume":"24","author":"C Fontaine-Sylvestre","year":"2021","unstructured":"Fontaine-Sylvestre C, Letourneau-Guillon L, Moumdjian RA, Berthelet F, Lacroix A (2021) Corticotroph tumor progression during long-term therapy with osilodrostat in a patient with persistent Cushing\u2019s disease. Pituitary 24(2):207\u2013215. https:\/\/doi.org\/10.1007\/s11102-020-01097-1","journal-title":"Pituitary"},{"issue":"5","key":"1268_CR23","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2013-3628","volume":"99","author":"F Castinetti","year":"2014","unstructured":"Castinetti F, Guignat L, Giraud P, Muller M, Kamenicky P, Drui D et al (2014) Ketoconazole in Cushing\u2019s disease: is it worth a try? J Clin Endocrinol Metab 99(5):1623\u20131630. https:\/\/doi.org\/10.1210\/jc.2013-3628","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1268_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1530\/EJE-07-0514","volume":"158","author":"F Castinetti","year":"2008","unstructured":"Castinetti F, Morange I, Jaquet P, Conte-Devolx B, Brue T (2008) Ketoconazole revisited: a preoperative or postoperative treatment in Cushing\u2019s disease. Eur J Endocrinol 158(1):91\u201399. https:\/\/doi.org\/10.1530\/EJE-07-0514","journal-title":"Eur J Endocrinol"},{"key":"1268_CR25","doi-asserted-by":"publisher","unstructured":"Fleseriu M, Pivonello R, Elenkova A, Salvatori R, Auchus RJ, Feelders RA, et al (2019) Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing\u2019s syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. Lancet Diabetes Endocrinol 7(11):855\u2013865. https:\/\/doi.org\/10.1016\/S2213-8587(19)30313-4. Erratum corrected in: Lancet Diabetes Endocrinol 7(11):e22. https:\/\/doi.org\/10.1016\/S2213-8587(19)30322-5","DOI":"10.1016\/S2213-8587(19)30313-4 10.1016\/S2213-8587(19)30322-5"},{"issue":"10","key":"1268_CR26","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M et al (2012) A 12-month phase 3 study of pasireotide in Cushing\u2019s disease. N Engl J Med 366(10):914\u2013924. https:\/\/doi.org\/10.1056\/NEJMoa1105743","journal-title":"N Engl J Med"},{"issue":"1","key":"1268_CR27","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1210\/jc.2008-1533","volume":"94","author":"R Pivonello","year":"2009","unstructured":"Pivonello R, De Martino MC, Cappabianca P, De Leo M, Faggiano A, Lombardi G et al (2009) The medical treatment of Cushing\u2019s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 94(1):223\u2013230. https:\/\/doi.org\/10.1210\/jc.2008-1533","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1268_CR28","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jpainsymman.2006.08.013","volume":"33","author":"L Margolin","year":"2007","unstructured":"Margolin L, Cope DK, Bakst-Sisser R, Greenspan J (2007) The steroid withdrawal syndrome: a review of the implications, etiology, and treatments. J Pain Symptom Manage 33(2):224\u2013228. https:\/\/doi.org\/10.1016\/j.jpainsymman.2006.08.013","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"1268_CR29","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3390\/diagnostics11040728","volume":"11","author":"K Pelewicz","year":"2021","unstructured":"Pelewicz K, Miskiewicz P (2021) Glucocorticoid withdrawal\u2014an overview on when and how to diagnose adrenal insufficiency in clinical practice. Diagnostics (Basel) 11(4):728. https:\/\/doi.org\/10.3390\/diagnostics11040728","journal-title":"Diagnostics (Basel)"},{"issue":"2","key":"1268_CR30","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1530\/eje.1.01953","volume":"153","author":"A Bhattacharyya","year":"2005","unstructured":"Bhattacharyya A, Kaushal K, Tymms DJ, Davis JR (2005) Steroid withdrawal syndrome after successful treatment of Cushing\u2019s syndrome: a reminder. Eur J Endocrinol 153(2):207\u2013210. https:\/\/doi.org\/10.1530\/eje.1.01953","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1268_CR31","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ecl.2005.01.013","volume":"34","author":"RL Hopkins","year":"2005","unstructured":"Hopkins RL, Leinung MC (2005) Exogenous Cushing\u2019s syndrome and glucocorticoid withdrawal. Endocrinol Metab Clin North Am 34(2):371\u2013384. https:\/\/doi.org\/10.1016\/j.ecl.2005.01.013","journal-title":"Endocrinol Metab Clin North Am"},{"key":"1268_CR32","unstructured":"Elshimy G, Chippa V, Jeong JM (2021) Adrenal Crisis. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island"},{"issue":"OC8","key":"1268_CR33","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1530\/endoabs.73.OC8.2","volume":"73","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Biller B, Pivonello R, Akira S, Carla S, Belaya Z et al (2021) Osilodrostat is an effective and well-tolerated treatment option for patients with Cushing\u2019s disease (CD): final results from the LINC3 study. Endocr Abstr 73(OC8):2. https:\/\/doi.org\/10.1530\/endoabs.73.OC8.2","journal-title":"Endocr Abstr"},{"issue":"6","key":"1268_CR34","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.1016\/j.eprac.2021.04.707","volume":"27","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Archus RJ, Snyder PJ, Lacroix A, Heaney AP, Geer EB et al (2021) Effect of dosing and titration of osilodrostat on efficacy and safety in patients with Cushing\u2019s disease (CD): results from two phase III trials (LINC 3 and LINC 4). Endocr Pract 27(6):S112. https:\/\/doi.org\/10.1016\/j.eprac.2021.04.707","journal-title":"Endocr Pract"},{"key":"1268_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14551","author":"F Castinetti","year":"2021","unstructured":"Castinetti F, Amodru V, Brue T (2021) Osilodrostat in Cushing\u2019s disease: the risk of delayed adrenal insufficiency should be carefully monitored. Clin Endocrinol (Oxf). [Epub July 5, 2021]. https:\/\/doi.org\/10.1111\/cen.14551","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"1268_CR36","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1056\/NEJMra1807486","volume":"381","author":"RL Rushworth","year":"2019","unstructured":"Rushworth RL, Torpy DJ, Falhammar H (2019) Adrenal crisis. N Engl J Med 381(9):852\u2013861. https:\/\/doi.org\/10.1056\/NEJMra1807486","journal-title":"N Engl J Med"},{"key":"1268_CR37","doi-asserted-by":"publisher","first-page":"204201881984821","DOI":"10.1177\/2042018819848218","volume":"10","author":"R Dineen","year":"2019","unstructured":"Dineen R, Thompson CJ, Sherlock M (2019) Adrenal crisis: prevention and management in adult patients. Ther Adv Endocrinol Metab 10:2042018819848218. https:\/\/doi.org\/10.1177\/2042018819848218","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"11","key":"1268_CR38","doi-asserted-by":"publisher","first-page":"13228","DOI":"10.3390\/molecules181113228","volume":"18","author":"LM Bloem","year":"2013","unstructured":"Bloem LM, Storbeck KH, Schloms L, Swart AC (2013) 11beta-hydroxyandrostenedione returns to the steroid arena: biosynthesis, metabolism and function. Molecules 18(11):13228\u201313244. https:\/\/doi.org\/10.3390\/molecules181113228","journal-title":"Molecules"},{"issue":"3","key":"1268_CR39","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ecl.2020.05.003","volume":"49","author":"NA Tritos","year":"2020","unstructured":"Tritos NA, Biller BMK (2020) Advances in the medical treatment of Cushing disease. Endocrinol Metab Clin North Am 49(3):401\u2013412. https:\/\/doi.org\/10.1016\/j.ecl.2020.05.003","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"9","key":"1268_CR40","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.eprac.2021.06.012","volume":"27","author":"KCJ Yuen","year":"2021","unstructured":"Yuen KCJ (2021) Osilodrostat: a review of recent clinical studies and practical recommendations for its use in the treatment of Cushing disease. Endocr Pract 27(9):956\u2013965. https:\/\/doi.org\/10.1016\/j.eprac.2021.06.012","journal-title":"Endocr Pract"},{"issue":"6","key":"1268_CR41","doi-asserted-by":"publisher","first-page":"S130","DOI":"10.1016\/j.eprac.2021.04.744","volume":"27","author":"R Pivonello","year":"2021","unstructured":"Pivonello R, Fleseriu M, Newell-Price J, Shimatsu A, Feelders RA, Kadioglu P et al (2021) Effect of osilodrostat on clinical signs, physical features and health-related quality of life (HRQoL) by degree of mUFC control in patients with Cushing\u2019s disease (CD): results from the LINC3 study. Endocr Pract 27(6):S130\u2013S131. https:\/\/doi.org\/10.1016\/j.eprac.2021.04.744","journal-title":"Endocr Pract"},{"issue":"5","key":"1268_CR42","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s41574-020-0336-x","volume":"16","author":"AF Turcu","year":"2020","unstructured":"Turcu AF, Rege J, Auchus RJ, Rainey WE (2020) 11-Oxygenated androgens in health and disease. Nat Rev Endocrinol 16(5):284\u2013296. https:\/\/doi.org\/10.1038\/s41574-020-0336-x","journal-title":"Nat Rev Endocrinol"},{"issue":"suppl 1","key":"1268_CR43","doi-asserted-by":"publisher","first-page":"A521","DOI":"10.1210\/jendso\/bvab048.1063","volume":"5","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Biller BMK, Bertherat J, Young J, Arnaldi G, O\u2019Connell P et al (2021) Long-term control of urinary free cortisol with osilodrostat in patients with Cushing\u2019s disease: final results from the LINC 2 study. J Endocr Soc 5(suppl 1):A521\u2013A522. https:\/\/doi.org\/10.1210\/jendso\/bvab048.1063","journal-title":"J Endocr Soc"},{"issue":"1","key":"1268_CR44","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-20-0352","volume":"183","author":"J Newell-Price","year":"2020","unstructured":"Newell-Price J, Nieman LK, Reincke M, Tabarin A (2020) Endocrinology in the time of COVID-19: management of Cushing\u2019s syndrome. Eur J Endocrinol 183(1):G1\u2013G7. https:\/\/doi.org\/10.1530\/EJE-20-0352","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"1268_CR45","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S2213-8587(20)30149-2","volume":"8","author":"AM Isidori","year":"2020","unstructured":"Isidori AM, Pofi R, Hasenmajer V, Lenzi A, Pivonello R (2020) Use of glucocorticoids in patients with adrenal insufficiency and COVID-19 infection. Lancet Diabetes Endocrinol 8(6):472\u2013473. https:\/\/doi.org\/10.1016\/S2213-8587(20)30149-2","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"1268_CR46","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s11102-021-01148-1","volume":"24","author":"S Frara","year":"2021","unstructured":"Frara S, Allora A, Castellino L, di Filippo L, Loli P, Giustina A (2021) COVID-19 and the pituitary. Pituitary 24(3):465\u2013481. https:\/\/doi.org\/10.1007\/s11102-021-01148-1","journal-title":"Pituitary"},{"key":"1268_CR47","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s11154-021-09672-y","volume":"23","author":"S Frara","year":"2022","unstructured":"Frara S, Loli P, Allora A, Santini C, di Filippo L, Mortini P et al (2022) COVID-19 and hypopituitarism. Rev Endocr Metab Disord 23:215\u2013231. https:\/\/doi.org\/10.1007\/s11154-021-09672-y","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"1268_CR48","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S2213-8587(21)00291-6","volume":"10","author":"W Kanczkowski","year":"2022","unstructured":"Kanczkowski W, Evert K, Stadtmuller M, Haberecker M, Laks L, Chen L-S et al (2022) COVID-19 targets human adrenal glands. Lancet Diabetes Endocrinol 10(1):13\u201316. https:\/\/doi.org\/10.1016\/S2213-8587(21)00291-6","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"1268_CR49","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/S2213-8587(20)30215-1","volume":"8","author":"R Pivonello","year":"2020","unstructured":"Pivonello R, Ferrigno R, Isidori AM, Biller BMK, Grossman AB, Colao A (2020) COVID-19 and Cushing\u2019s syndrome: recommendations for a special population with endogenous glucocorticoid excess. Lancet Diabetes Endocrinol 8(8):654\u2013656. https:\/\/doi.org\/10.1016\/S2213-8587(20)30215-1","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1268_CR50","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3389\/fendo.2020.00554","volume":"11","author":"F Beretta","year":"2020","unstructured":"Beretta F, Dassie F, Parolin M, Boscari F, Barbot M, Busetto L et al (2020) Practical considerations for the management of Cushing\u2019s disease and COVID-19: a case report. Front Endocrinol (Lausanne) 11:554. https:\/\/doi.org\/10.3389\/fendo.2020.00554","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1268_CR51","doi-asserted-by":"publisher","first-page":"656025","DOI":"10.3389\/fendo.2021.656025","volume":"12","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M (2021) Pituitary disorders and COVID-19, reimagining care: the pandemic a year and counting. Front Endocrinol (Lausanne) 12:656025. https:\/\/doi.org\/10.3389\/fendo.2021.656025","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"1268_CR52","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11102-011-0333-0","volume":"15","author":"H Raff","year":"2012","unstructured":"Raff H (2012) Cushing\u2019s syndrome: diagnosis and surveillance using salivary cortisol. Pituitary 15(1):64\u201370. https:\/\/doi.org\/10.1007\/s11102-011-0333-0","journal-title":"Pituitary"},{"issue":"2","key":"1268_CR53","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/cphy.c130035","volume":"4","author":"H Raff","year":"2014","unstructured":"Raff H, Sharma ST, Nieman LK (2014) Physiological basis for the etiology, diagnosis, and treatment of adrenal disorders: Cushing\u2019s syndrome, adrenal insufficiency, and congenital adrenal hyperplasia. Compr Physiol 4(2):739\u2013769. https:\/\/doi.org\/10.1002\/cphy.c130035","journal-title":"Compr Physiol"},{"issue":"2","key":"1268_CR54","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1530\/EJE-19-0695","volume":"182","author":"J Newell-Price","year":"2020","unstructured":"Newell-Price J, Pivonello R, Tabarin A, Fleseriu M, Witek P, Gadelha MR et al (2020) Use of late-night salivary cortisol to monitor response to medical treatment in Cushing\u2019s disease. Eur J Endocrinol 182(2):207\u2013217. https:\/\/doi.org\/10.1530\/EJE-19-0695","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1268_CR55","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1007\/s12020-016-0978-6","volume":"54","author":"JW Findling","year":"2016","unstructured":"Findling JW, Fleseriu M, Newell-Price J, Petersenn S, Pivonello R, Kandra A et al (2016) Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing\u2019s disease: 12-month, phase III pasireotide study. Endocrine 54(2):516\u2013523. https:\/\/doi.org\/10.1007\/s12020-016-0978-6","journal-title":"Endocrine"},{"issue":"9","key":"1268_CR56","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1210\/jc.2017-00823","volume":"102","author":"M Debono","year":"2017","unstructured":"Debono M, Harrison RF, Chadarevian R, Gueroult C, Abitbol JL, Newell-Price J (2017) Resetting the abnormal circadian cortisol rhythm in adrenal incidentaloma patients with mild autonomous cortisol secretion. J Clin Endocrinol Metab 102(9):3461\u20133469. https:\/\/doi.org\/10.1210\/jc.2017-00823","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1268_CR57","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1507\/endocrj.EJ19-0617","volume":"67","author":"T Tanaka","year":"2020","unstructured":"Tanaka T, Satoh F, Ujihara M, Midorikawa S, Kaneko T, Takeda T et al (2020) A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11beta-hydroxylase inhibitor, in Japanese patients with endogenous Cushing\u2019s syndrome other than Cushing\u2019s disease. Endocr J 67(8):841\u2013852. https:\/\/doi.org\/10.1507\/endocrj.EJ19-0617","journal-title":"Endocr J"},{"issue":"4","key":"1268_CR58","doi-asserted-by":"publisher","first-page":"L7","DOI":"10.1530\/EJE-20-0557","volume":"183","author":"M Haissaguerre","year":"2020","unstructured":"Haissaguerre M, Puerto M, Nunes ML, Tabarin A (2020) Efficacy and tolerance of osilodrostat in patients with severe Cushing\u2019s syndrome due to non-pituitary cancers. Eur J Endocrinol 183(4):L7\u2013L9. https:\/\/doi.org\/10.1530\/EJE-20-0557","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1268_CR59","doi-asserted-by":"publisher","first-page":"K1","DOI":"10.1530\/eje-21-1008","volume":"186","author":"A Tabarin","year":"2022","unstructured":"Tabarin A, Haissaguerre M, Lassole H, Jannin A, Paepegaey AC, Chabre O et al (2022) Efficacy and tolerance of osilodrostat in patients with Cushing\u2019s syndrome due to adrenocortical carcinomas. Eur J Endocrinol 186(2):K1\u2013K4. https:\/\/doi.org\/10.1530\/eje-21-1008","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1268_CR60","doi-asserted-by":"publisher","first-page":"L13","DOI":"10.1530\/EJE-21-0147","volume":"184","author":"L Bessi\u00e8ne","year":"2021","unstructured":"Bessi\u00e8ne L, Bonnet F, Tenenbaum F, Jozwiak M, Corchia A, Bertherat J et al (2021) Rapid control of severe ectopic Cushing\u2019s syndrome by oral osilodrostat monotherapy. Eur J Endocrinol 184(5):L13\u2013L15. https:\/\/doi.org\/10.1530\/EJE-21-0147","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"1268_CR61","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1210\/jc.2011-0536","volume":"96","author":"P Kamenick\u00fd","year":"2011","unstructured":"Kamenick\u00fd\u00a0P, Droumaguet C, Salenave S, Blanchard A, Jublanc C, Gautier J-F et al (2011) Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing\u2019s syndrome. J Clin Endocrinol Metab 96(9):2796\u20132804. https:\/\/doi.org\/10.1210\/jc.2011-0536","journal-title":"J Clin Endocrinol Metab"},{"key":"1268_CR62","unstructured":"Janssen Pharmaceuticals (2013) Nizoral prescribing information. Accessed from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/018533s040lbl.pdf"},{"key":"1268_CR63","unstructured":"HRA Pharma Rare Diseases (2020) Metopirone prescribing information. Accessed from https:\/\/metopirone.com\/wp-content\/uploads\/2019\/11\/Metopirone_US_PI-rev.02.2020.pdf"},{"key":"1268_CR64","unstructured":"Bristol-Myers Squibb Company (2019) Lysodren prescribing information. Accessed from https:\/\/packageinserts.bms.com\/pi\/pi_lysodren.pdf"},{"issue":"2","key":"1268_CR65","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/17446651.2022.2044789","volume":"17","author":"M Martino","year":"2022","unstructured":"Martino M, Aboud N, Lucchetti B, Salvio G, Arnaldi G (2022) Osilodrostat oral tablets for adults with Cushing\u2019s disease. Expert Rev Endocrinol Metab 17(2):99\u2013109. https:\/\/doi.org\/10.1080\/17446651.2022.2044789","journal-title":"Expert Rev Endocrinol Metab"},{"key":"1268_CR66","unstructured":"Hospira (2017) Amidate prescribing information. Accessed from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/018227s032lbl.pdf"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01268-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-022-01268-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01268-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T10:49:04Z","timestamp":1668854944000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-022-01268-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":66,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1268"],"URL":"https:\/\/doi.org\/10.1007\/s11102-022-01268-2","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]},"assertion":[{"value":"25 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MF reports serving as an investigator with research grants to Oregon Health and Science University from Millendo Therapeutics, Novartis, Recordati, and Strongbridge Biopharma; has received occasional scientific consulting honoraria from HRA Pharma, Novartis, Recordati, Sparrow Pharmaceuticals, and Strongbridge Biopharma; served as a member of the LINC 3 steering committee; and is a member of the editorial board for <i>Pituitary<\/i>. BMKB reports research grants to her institution from Millendo Therapeutics, Novartis, and Strongbridge Biopharma; has received occasional consulting honoraria from HRA Pharma, Recordati, Sparrow Pharmaceuticals, and Strongbridge Biopharma; and served on the LINC 3 steering committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}